Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive‐Stage Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive‐stage SCLC (ES‐SCLC). Although ES‐SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Im...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Melosky, Barbara, Cheema, Parneet K., Brade, Anthony, McLeod, Deanna, Liu, Geoffrey, Price, Paul Wheatley, Jao, Kevin, Schellenberg, Devin D., Juergens, Rosalyn, Leighl, Natasha, Chu, Quincy
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Lung Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648366/
https://ncbi.nlm.nih.gov/pubmed/32860288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0193
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars